Alerts
2023
October
September
August
July
May
January
2022
December
November
August
July
June
May
April
March
2021
December
November
October
September
August
July
June
May
April
March
February
January
2020
December
November
October
September
August
July
June
May
April
March
February
January
2019
December
November
October
September
August
July
June
May
April
March
February
January
2018
December
November
October
September
August
July
June
May
April
March
February
January
2017
December
November
October
September
August
July
June
May
April
March
February
January
2016
December
November
October
September
August
July
June
May
April
March
February
January
2015
December
November
October
September
August
July
June
May
April
March
February
January
2014
December
November
October
September
August
July
June
May
April
March
February
January
2013
December
- 2023
- October
- September
- August
- July
- May
- January
- 2022
- December
- November
- August
- July
- June
- May
- April
- March
- 2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2017
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2016
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2015
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2014
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- 2013
- December
Sanofi US to Return Auvi-Q® (epinephrine injection, USP) Rights to kaléo
February 28, 2016
Sanofi announced today that the license and development agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® (epinephrine injection, USP), will terminate later this year. At that time, all U.S. and Canadian rights will be returned to kaléo. Sanofi is in discussions with kaléo on these terms and for an orderly transition plan. Kaléo will evaluate timing and options for bringing Auvi-Q back to market. Please refer to the web site for further details: